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Background: Hereditary myopathy with early respiratory failure (HMERF) was described in several North European
families and recently linked to a titin gene (TTN) mutation. We independently studied HMERF-like diseases with the
purpose to identify the cause, refine diagnostic criteria, and estimate the frequency of this disease among
myopathy patients of various ethnic origins.
Methods: Whole exome sequencing analysis was carried out in a large U.S. family that included seven members
suffering from skeletal muscle weakness and respiratory failure. Subsequent mutation screening was performed in
further 45 unrelated probands with similar phenotypes. Studies included muscle strength evaluation, nerve
conduction studies and concentric needle EMG, respiratory function test, cardiologic examination, and muscle
biopsy.
Results: A novel TTN p.Gly30150Asp mutation was identified in the highly conserved A-band of titin that co-segregated
with the disease in the U.S. family. Screening of 45 probands initially diagnosed as myofibrillar myopathy (MFM) but
excluded based on molecular screening for the known MFM genes led to the identification of a previously reported TTN
p.Cys30071Arg mutation in one patient. This same mutation was also identified in a patient with suspected HMERF. The
p.Gly30150Asp and p.Cys30071Arg mutations are localized to a side chain of fibronectin type III element A150 of the 10th
C-zone super-repeat of titin.
Conclusions: Missense mutations in TTN are the cause of HMERF in families of diverse origins. A comparison of
phenotypic features of HMERF caused by the three known TTN mutations in various populations allowed to emphasize
distinct clinical/pathological features that can serve as the basis for diagnosis. The newly identified p.Gly30150Asp and the
p.Cys30071Arg mutation are localized to a side chain of fibronectin type III element A150 of the 10th C-zone super-repeat
of titin.
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Hereditary myopathy with early respiratory failure
(HMERF) also known as Edström myopathy is a disorder
manifesting with predominantly proximal muscle weak-
ness of the lower and upper extremities with respiratory
insufficiency and involvement of neck flexors early in
the disease course [1]. A number of cases showing auto-
somal dominant pattern of inheritance and sporadic
cases have been reported [2-4]. A distinctive pathological
feature of HMERF is the presence of cytoplasmic bodies.
The first TTN mutation causing HMERF has been iden-
tified by Lange and colleagues [5] in Swedish families
originally described by Edström et al. [1]. This mutation
was defined as p.Arg279Trp by using residue numbe-
ring according to the crystal structure of the titin ki-
nase domain [6]. Based on updated databases (GenBank
NP_001243779 and UniProt Q8WZ42), the mutant resi-
due has been re-numbered as p.Arg32450Trp [7]. Recently,
HMERF in several newer North European families have
been associated with a g.274375T>C: p.Cys30071Arg muta-
tion in the A-band of titin [7,8].
TTN mutations have been known to cause other
neuromuscular and cardiac disorders, among them
dilated cardiomyopathy type 1G [9] and neuromuscular
disorders such as tibial muscular dystrophy (TMD), or
Udd myopathy [10], limb–girdle muscular dystrophy
type 2J (LGMD2J) [11,12], and autosomal recessive early-
onset myopathy with fatal cardiomyopathy (EOMFC) [13].
Mutations associated with dilated cardiomyopathy are
overrepresented in the titin A-band [14]; the mutation
identified in Swedish HMERF families by Lange et al. [5]
is in the titin protein kinase domain, while mutations for
TMD, LGMD2J, and EOMFC are located in the C-terminal
end of the M-band.
Titin is the largest muscle protein known, a filamentous
molecule stretching for half-sarcomere, from the Z-disk
(N-terminus) spanning the A-band and extending to the
M-band (C-terminus) [15]. Titin isoform of skeletal
muscle is composed of >33,000 amino acids, weighs 3,700
kD, and its length is 2 μm [16]. Titin has a modular struc-
ture; up to 90% of its mass consists of repeating
immunoglobulin-like (Ig) and fibronectin type III (FN3)
domains. Titin serves as a molecular template for the
assembly of the myosin-based filament and is responsible
for the stabilization of the thick filament and the struc-
tural integrity of the entire sarcomere by acting as a scaf-
fold [17]. Titin is a molecular spring that provides
elasticity to the sarcomere and ensures its return to the
original length after muscle relaxation [18]. Titin is also
involved in signal transduction from the myofibrils to
other compartments of the muscle cell, including the nu-
cleus [19].
The elastic part of titin is its I-band region com-
posed of 40 Ig-domains; the A-band is stable and notextensible due to its strong interaction with the thick
filament [20,21]. The A-band is composed of stretches
of FN3 domains interspaced by single Ig domains,
forming the unique titin super-repeat architecture. The
N-terminal super-repeat within the A-band (D-zone)
comprises six copies of a 7-element structure arranged
as Ig-(FN3)2-Ig-(FN3)3. The second super-repeat located
C-terminally (C-zone) is organized into eleven copies of
an 11-element motif arranged as Ig-(FN3)2-Ig-(FN3)3-
Ig-(FN3)3 [22]. The two super-repeats of the A-band
region provide regularly spaced binding sites for compo-
nents of the thick filaments [17,23,24] and serve as a
molecular ruler that regulates the assembly and the
length of the thick filament [25]. FN3 elements provide
binding sites for myosin, while Ig-like domains may be
responsible for interaction with other ligands. A-band is
evolutionarily conserved, unlike the Z-disk and I-band
segments of titin that are highly divergent [18]. Titin
kinase domain contains a catalytic domain and an auto-
regulatory C-terminal tail [6], which wraps the active site
of the catalytic domain. The p.Arg32450Trp mutation is
located at the N-terminal helix (alphaR1) of the kinase
domain [5]. TTN gene is positioned in the 2q31 chromo-
some region and consists of 363 exons.
In the process of genetic testing of patients with myo-
fibrillar myopathy (MFM) we encountered familial and
sporadic cases of skeletal myopathy with or without
associated respiratory abnormalities who lack mutations
in MFM-associated genes [26,27]. To identify a causative
mutation in affected members of a large U.S. family
suffering from proximal myopathy and respiratory fail-
ure we carried out whole exome sequencing and deter-
mined that the mutation was in the TTN gene.
Screening of other families led to the identification of a
similar mutation in affected individuals from two other
families originating from a Native American population
in Canada and from Spain, indicating that missense
mutations in TTN are the cause of HMERF in families
of divergent origins. We compared phenotypic features
of HMERF in three families under our study with previ-
ously reported clinical/pathological descriptions of the
disease caused by three TTN mutations in various popu-
lations and refined diagnostic criteria of HMERF. Both
p.Gly30150Asp and p.Cys30071Arg TTN mutations
disrupt a fibronectin type III element of titin A-band
super-repeat designated as A150.
Methods
Clinical and laboratory evaluation
We studied in detail 7 patients from three unrelated
families reffered to as families A, B, and C suffering from
skeletal myopathy and respiratory failure. Studies included
muscle strength evaluation according to the Medical
Research Council (MRC) grading scale, serum CK level
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needle EMG, respiratory function test, and cardiologic
examination. In one patient muscle CT scan images were
obtained from the pelvis, mid-thigh and mid-calf levels.
Written consent was obtained for each element of this
study. Genetic studies were approved by the Institutional
Review Board of the National Institute of Neurological
Disorders and Stroke in Bethesda, Maryland.
Muscle biopsy
An open muscle biopsy was performed for diagnostic
purposes in at least one affected patient per family.
Muscle tissue was obtained from the deltoid, biceps,
quadriceps or gastrocnemius muscles. Biopsies were
taken one to 14 years after the initial symptoms. The
samples were immediately frozen in liquid nitrogen-
cooled isopentane and processed for routine histochemical
reactions. Immunocytochemical analysis was performed
using antibodies against desmin and vimentin in 4 patients
of family A and myotilin, dystrophin, αB-crystallin, and
filamin C in a patient of family C as previously described
[27]. In addition, muscle sections from the proband of
family B were processed for TDP43 immunohistochemis-
try using a rabbit polyclonal (ProteinTech, Chicago, Ill).
Pieces of biopsied tissue from the proband of family B and
C were processed for ultrastructural examination using
standard methods.
Whole exome sequencing and SNP analysis
Genomic DNA was extracted from peripheral blood
samples according to standard protocols. DNA samples
from five affected subjects, II:3, II:4, II:6, III:1, and III:3
of family A (Figure 1), were subjected to whole-exome
sequencing (WES). Exon enrichment was performed
using the Sureselect Human All Exon capture systemFigure 1 Pedigree of the U.S. family (Family A).(Agilent Technologies Inc, Santa Clara, CA) following
the manufacturer protocol. DNA library consisting of
paired end reads was sequenced on a Genomic Analyser
IIx sequencer (Illumina Inc, San Diego, CA). Library
construction, sequence generation, sequence alignment
to the reference genome and variant calling were
described in detail elsewhere [28,29].
Mutation screening
Mutation screening by conventional Sanger sequencing
was performed in all members of the affected families.
In addition, a cohort of 45 unrelated subjects consisting
of 11 patients with predominantly proximal weakness,
respiratory failure and/or cardiomyopathy, 8 cases with
predominantly proximal myopathy, and 26 cases with
initial distal muscle involvement subsequently progressing
to proximal limb weakness were also screened for TTN
mutations. The 45 patients have previously been tested
for mutations in MFM-associated and other neuromus-
cular genes (DES, MYOT, LDB3, CRYAB, BAG3, FLNC,
and FHL1) with negative results. Most of the 45 patients
originated from North America (U.S. and Canada) and
European countries (France, Germany, Poland). Finally,
we studied a Spanish patient recently classified as suffer-
ing from HMERF on the basis of clinical and pathological
data. The screening was done for the following TTN mu-
tations associated with HMERF: p.Gly30150Asp identified
in the current study, p.Cys30071Arg recently identified in
North European families [7,8], and the kinase domain
p.Arg32450Trp mutation [5]. Initial screening in the co-
hort of 45 patients was performed by digesting of ampli-
fied exons with restriction enzymes NlaIII, BstNI, and
MspI recognizing these mutations, followed by validation
of the presence of a TTN mutation by using standard
Sanger sequencing of amplified TTN exons. Primers were




Family A. Five members of the U.S. family (Figure 1)
were studied in detail. They presented between the ages
of 13 to 29 with proximal weakness in the lower extrem-
ities manifesting with difficulty on stairs or rising up
from a squatting position (Table 1). Over the following
several years, the weakness spread to distal leg muscles,
upper limbs and neck. Within 10 years after the disease
onset, older patients (II:1, II:3 and II:6) developed
respiratory failure necessitating nocturnal ventilator sup-
port and all died before the age of 65 years of respiratory
failure. Their father and grandfather suffered from the
same disease and died from respiratory failure at ages 52
and 50 years, respectively. None of the patients had
cardiac symptoms. Examination of three patients (II:3,
Table 1 Phenotypic characteristics of patients with titin p.Gly30150Asp and p.Cys30071Arg mutations
Family, Country Family A Family B Family C
U.S., European ancestry Canada, East
Indian
Spain
TTN Mutation p.Gly30150Asp p.Cys30071Arg
Patient (II:3) (II:4) (II:6) (III:1) (III:3) (Index) (Index)
Age at onset 29 17 22 13 14 22 36
Age at exam 37 33 29 14 14 26 41
Age at wheelchair 38 - 31 - - 32 -
Age at respiratory failure 39 - 37 - - 26 37
Muscles affected at
presentation







Facial muscles 5 5 5 5 5 5 5
Neck flexion 4 4+ 4+ 4+ 5- 5 4
Neck extension 4 5 5 5 5 5 5
Shoulder abduction 4 5 3- 5 5- 4 5
Shoulder adduction 5 4+ 4 5 5- 4 5
Elbow flexion 5- 5 5 5 5 5 5
Elbow extension 4+ 5 4 5 5 4 5
Wrist flexion 4+ 5 4 5 5 4 5
Wrist extension 4+ 5 4 5 5 4 4
Finger flexion 4+ 5 4 5 5 5 5
Finger extension 4+ 5 4 4+ 5 4+ 4
Intrinsic hand muscles 4+ 5 4+ 5 5 4+ 5
Hip flexion 3- 4+ 3- 4 5- 2 3
Hip abduction 4 4 3- 5 5 3 4+
Knee flexion (hamstrings) 4 4+ 2 5 5 4 5
Knee extension (quadriceps) 4 4+ 3- 5 5 2 4
Ankle dorsiflexion (anterior
tibialis)
4 4+ 2 4+ 4+ 3 4
Ankle plantar flexion
(gastrocnemius)
4+ 4+ 2+ 5 5 5 5
Toe dorsiflexion 4 4+ 2 4+ 5 3 2
Toe plantar flexion 4+ 4+ 4+ 5 5 5 5
Gait while ambulant Waddling Waddling Waddling,
steppage








none none none none
Bilateral calf hypertrophy yes yes yes yes no yes no
Pulmonary function restriction normal restriction normal normal Severe restriction Severe
restriction
Dyspnea yes no yes no no yes yes
Cardiomyopathy no no no no no no no
CK levels nt nt 2-fold-increased nt normal Mildly-increased 2-fold-
increased
EMG - Myogenic with
spontaneous activity
nt nt yes nt nt yes yes
LL – lower limbs; nt – not tested.
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Figure 2 Muscle CT scans performed in a patient from family C
five years after the initial symptoms. At the pelvic region, the
gluteus minimus and medius, and especially the iliopsoas (arrows)
and rectus abdominis (double arrows) are severely affected (a).
Selective involvement of the semitendinosus, sartorius, and gracilis
muscles at mid-thigh level (b). At the mid-lower-leg level the
anterior tibialis and the peroneal group are involved, while muscles
of the posterior compartment were well preserved (c).
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flexors, pectoralis muscles, wrist and finger extensors
and flexors, and to a lesser degree intrinsic hand
muscles. In the lower limbs, weakness predominated in
iliopsoas, hip abductors, ankle and toe dorsiflexors.
There was wasting of the trapezius, sternocleidomastoid
and calf muscles, but each patient had initially bilateral
calf hypertrophy (Table 1). Examination of the two
younger patients (III:1 and III:3) within a year of initial
symptoms showed weakness in neck flexors, iliopsoas,
and ankle dorsiflexors, but no respiratory deficiency
(Table 1). Serum CK levels investigated in two patients
were found to be normal to two-fold increased. EMG
examination in one patient revealed a myogenic re-
cruitment pattern with prominent spontaneous activity
at rest.
Family B.A 26-year-old Native American woman
originating from East Indian population of Canada
presented at the age of 25 with bilateral foot drop. One
year later she developed severe respiratory failure requir-
ing orotracheal intubation. On examination, muscles
innervated by cranial nerves were intact. She had bilat-
eral calf hypertrophy and weakness of the deltoids,
iliopsoas, hip abductors, quadriceps, knee flexors, and
ankle dorsiflexors (Table 1). CK levels were increased 2-
fold. Her older sister presented with muscle weakness and
respiratory symptoms at the age of 27 years and died at 35
of respiratory failure. Their father, paternal uncle and aunt
had similar symptoms and died in their 40s.
Family C. A 41-year-old Spanish woman presented at
the age of 36 years with difficulty on stairs. Over the
following year she experienced dyspnea on exertion and
was diagnosed with asthma. On examination, the
patient’s facial muscles were intact. She had weakness of
neck flexors, iliopsoas, quadriceps, hip abductors, anter-
ior tibialis, and toe extensor (Table 1). Deep tendon re-
flexes were preserved, and sensation was intact. Her gait
was waddling and she had bilateral foot drop. No muscle
atrophies or hypertrophies were observed (Table 1). CK
levels were 2-fold-increased. Respiratory function test re-
vealed restrictive respiratory insufficiency that was
treated with nocturnal ventilation support. The patient’s
mother had suffered from slowly progressing predomin-
antly lower limb muscle weakness from the age of 50
years, subsequently developed respiratory insufficiency
necessitating ventilatory support at the age of 70, and
died two years later from respiratory failure.
Muscle imaging data
Muscle CT scanning was performed in a patient from
family C five years after the initial symptoms. At the
pelvic region, the gluteus minimus and medius and espe-
cially the iliopsoas and rectus abdominis were severely
affected. At mid-thigh, there was selective involvementof the semitendinosus, sartorius, and gracilis muscles. At
the mid-lower-leg level, the anterior tibialis and peroneal
groups were affected, while muscles of the posterior
compartment were well preserved (Figure 2).
Muscle biopsy analysis
Myopathological abnormalities were consistent with a
myopathy that varied in severity between patients
depending on the stage of illness. The most prominent
findings were variation in fiber size with atrophic and
hypertrophic fibers, increased number of internal nuclei,
fiber splitting, increased connective tissue with areas of
fibro-fatty tissue replacement and rimmed vacuoles
(Figure 3 and Table 2). A characteristic finding in each
sample was the presence of small round well defined
myofibrillar inclusions of varying size referred to as cyto-
plasmic bodies. The cytoplasmic bodies were eosino-
philic on HE and red, purple or dark blue on modified
Gomori trichrome stain, and devoid of ATPase and
oxidative enzyme activities. They were at times localized
under the sarcolemma. Some severely damaged fibers
contained large diffuse polymorphic accumulations of
material displaying the same staining properties as the
Figure 3 Histological and histochemical (a, b and c) findings in m. gastrocnemius biopsy of a patient carrying a p.Cys30071Arg TTN
mutation (family B). Prominent structural changes with variation of fiber size and areas of fibrofatty tissue replacement; the majority of fibers
harbor collections of cytoplasmic bodies along with large diffuse polymorphic accumulations of material (a). Some fibers contain rimmed
vacuoles (arrows in b). Fiber regions occupied by the cytoplasmic bodies are devoid of oxidative activity (c). Resin semithin section shows typical
cytoplasmic bodies (d). Stains: a: modified trichrome; b: H&E; c: NADH; d: semithin section stained with toluidine blue.
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toluidine blue displayed the cytoplasmic bodies as multiple
dark blue accumulations, at times with a peripheral halo.
Immunohistochemical analysis revealed accumulation of
myotilin, filamin C, dystrophin and αB-crystallin within
the cytoplasmic bodies (Figure 4). Desmin was focallyTable 2 Pathology features in HMERF patients carrying titin p
Famil
TTN Mutation p.Gly301
Patient (II:3) (II:4) (II:6)
Age at onset 29 17 22
Age at biopsy 37 33 29
Biopsied muscle deltoid deltoid biceps
Variation of fiber size +++ ++ ++
Fibro-fatty tissue proliferation ++ + -
Internal nuclei +++ + +
Necrosis/phagocytosis + - -
Interstitial inflammation + - -
Cytoplasmic bodies + + +
Rimmed vacuoles ++ + ++
Uneven oxidative enzyme activity + + ++
Sarcoplasmic tubulofilaments - - -
Intranuclear tubulofilaments - - -
+ mild; ++ moderate; +++ severe; - not seen.increased in the surrounding area but not within the cyto-
plasmic bodies. TDP43 immunoreactivity was observed
adjacent to rimmed vacuoles and in areas around cyto-
plasmic bodies.
Under electron microscopy, muscle fibers with early
changes showed widening and streaming of the Z-lines.Gly30150Asp and p.Cys30071Arg mutations
y A Family B Family C
50Asp p.Cys30071Arg
(III:1) (III:3) Index Index
13 14 22 36
14 15 25 41
quadriceps quadriceps gastrocnemius quadriceps
+ - +++ +
- - +++ -
- - ++ +
- - + -
+ - - -
++ + +++ ++
+ + ++ +
- - ++ +
- - + -
- - + -
Figure 4 Immunohistochemical analysis of muscle tissue in patients with TTN mutations. Accumulation of dystrophin (a), myotilin (b), and
filamin C (c and e) in fiber regions containing cytoplasmic bodies. Desmin (d) is focally increased at the periphery of cytoplasmic bodies but not
within them. Aggregates of TDP43 (f) are seen adjacent to rimmed vacuoles (arrow in f) and around the cytoplasmic bodies.
Toro et al. BMC Neurology 2013, 13:29 Page 7 of 14
http://www.biomedcentral.com/1471-2377/13/29(Figure 5). There were abundant extensions of semi-
dense filamentous material oriented perpendicularly to
the Z-line and comprising the entire sarcomere length.
Many fibers contained collections of globular inclusions
composed of the same semidense filaments. Typical cy-
toplasmic bodies with a dense core and a peripheral
clear halo were also observed. More severely affected fi-
bers had areas of complete sarcomere disorganization
filled by collections of rods, remnants of filaments, cellu-
lar debris, and autophagic vacuoles. In a single patient
with advanced disease we identified intrasarcoplasmic
aggregates of tubulofilaments measuring 16 nm in dia-
meter running in parallel and frequently positioned in
areas adjacent to autophagic vacuoles (Figure 5). Also
detectable were dispersed and randomly oriented intra-
nuclear thin tubulofilaments of 10 nm.
Genetic analysis
Whole exome sequencing results. We identified the
sequence variants from all positions where there were
high-quality sequence bases. A number of sequential fil-
tering steps were used to rank variants and to identifypotentially pathogenic changes using Most Probable
Genotype (MPG) methodology [29]. Non-coding regions
and synonymous SNPs were excluded. Missense variants
were sorted by the degree of severity of functional dis-
ruption prediction using Conserved Domain-based Pre-
diction (CDPred http://research.nhgri.nih.gov/software/
CDPred/) [30]. In view of the severity, early age of onset
and high penetrance of the disease suggested by the
family pedigree, we further restricted our candidates
by excluding any variant reported to have occurred in
heterozygous or homozygous state in a clinically unaf-
fected adult cohort of 572 subjects (ClinSeq http://www.
genome.gov/20519355). The candidate variant position
had to have been successfully sequenced to ClinSeq
quality standards in at least 100 individuals. Finally,
we selected variants shared by five affected members
of Family A in heterozygous state, assuming a domi-
nant model.
We have identified a total of 5 variants (Table 3) that
fulfilled stringent analysis criteria. Based on information
regarding encoded proteins function, we considered
variants in CDC2 and TTN as likely candidate mutations
Figure 5 Ultrastructural images of muscle biopsy in patients with TTN p.Cys30071Arg mutation. Early lesions originate at the Z-lines.
Semi-dense filamentous material arises perpendicularly to the Z-lines and extends to the entire sarcomeric length (a and c). Multiple globular
inclusions composed of the same semi-dense filamentous material interspersed between preserved sarcomeres (b) or in fibers with sarcomeric
disorganization (c). A fiber area with focal dissolution of myofibrils and collections of nemaline bodies (d). An atrophic fiber with complete sarcomeric
destruction is replaced by remnants of filaments and collections of small nemaline bodies (e). Typical cytoplasmic bodies surrounded by clear halo and
autophagic vacuoles in a severely damaged fiber (f). Collections of sarcoplasmic tubulofilaments running in parallel (g). Intranuclear tubulofilaments
(h). Intranuclear tubulofilaments at higher magnification are seen randomly oriented (i).
Table 3 Variants identified by whole genome sequencing in Family A
Chr Genomic Location Mutation type Gene name Ref Allele Var Allele Protein change Deleterious-ness
(CPPred)
10 62214606 Nonsyn SNP CDC2 C T c.175C>T:p.Arg59Cys −10
2 179118837 Nonsyn SNP TTN C T c.90449G>A:p.
Gly30150Asp
−9
11 72144446 Nonsyn SNP NY-CO-28,
STARD10
C T c.578G>A:p.Gly193Asp −6
16 5080536 Nonsyn SNP FAM86A C A c.374G>T:p.Ser125Ile −2
18 65945866 Nonsyn SNP RTTN T C c.3235A>G:p.Ile1079Val 3
These variants (except for the CDC2 variant that is a rare polymorphism designated as rs8755) have been submitted to the GenBank; the accession numbers are
[GeneBank:JX424570] for the TTN variant, [GeneBank:JX424571] for the NY-CO-28,STARD10 variant, [GeneBank:JX424572] for the FAM86A variant, and [GeneBank:
JX424573] for the RTTN variant.







Figure 6 Screen capture for whole genome sequencing read
depth and read alignments using Integrated Genome Viewer
(IGV) for the five affected individuals of family A centered at
genome position chr2:179,118,837 (red/blue). Read depths (lines)
are scaled in a range of 0–200 for all five individuals. Red cross-lines
denote variant reads; the rare variant is present in some but not all
reads, indicating heterozygosity.
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Arg59Cys variant revealed complete co-segregation with
the disease phenotype (not shown). CDC2 is a member
of serine/threonine kinase family that phosphorylates
intermediate filament proteins, including desmin, and an
abnormal expression of CDC2 was found in patients
with MFM [31,32]. In light of these reports, we tested
expression of CDC2 protein in muscle extracts from an
affected subject. Immunoblot analysis with CDC2
specific antibody showed no difference in expression and
banding pattern of CDC2 in a patient from Family A
(II:4) compared to healthy control subjects (not shown),
which contradicts reported data [31]. In addition, the
CDC2 c.175C>T variant is present with a carrier
frequency of 0.12% in 4300 publicly available data of
exome sequencing in European Americans (NHLBI
Exome Sequencing Project/Exome Variant Server http://
evs.gs.washington.edu), suggesting that this is a rare
polymorphic variant occurring in the background popu-
lation (rs8755).
The second heterozygous variant g.274613G>A
(according to database AJ277892) detected in exon 343 of
the TTN gene was a more convincing candidate. It results
in a novel missense mutation c.90674G>A:p.Gly30150Asp
(according to databases NP_001243779 and Q8WZ42) that
changes a highly conserved neutral glycine to negatively
charged aspartic acid. Screen capture of whole exome se-
quencing (Figure 6) at genome position chr2:179,118,837
shows the presence of the mutation in each affected indi-
vidual; the variant is present in some but not all reads, indi-
cating heterozygosity. This variant is not reported in
ClinSeq 1000 Genomes database or the publicly available
data on exome sequencing of 6500 European and African
Americans (NHLBI Exome Sequencing Project/Exome
variant Server http://evs.gs.washington.edu/EVS). Both the
p. Cys30071Arg mutation recently identified in North
European families [7,8] and the p.Gly30150Asp mutation of
Family A are located in a fibronectin type III (FN3) element
within the 10th C-zone super-repeat (Figure 7). In this 10th
super-repeat structure(Ig–FN3–FN3–Ig–FN3–FN3–FN3–
Ig–FN3–FN3–FN3) the mutant fibronectin element is
the first of the three C-terminal FN3 repeats and is
numbering TTN A150 according to Bucher et al. [33].
FN3-s are known to bind the thick filament of muscle
and are highly conserved. Our testing of a structural
model of an FN3 titin domain (number A77) solved by
X-ray crystallography to 1.65 Å resolution [33] suggest
that mutated residues Cys30071 and Gly30150 are lo-
cated in the side chain that most likely serves as a
binding site (not shown).
Mutation screening. Both candidate variants, CDC2
c.175C>T:p.Arg59Cys and TTN c.90674G>A:p.Gly30150Asp
resulting from WES analysis were confirmed by Sanger
sequencing in all affected members of family A. Inaddition, a cohort of 45 molecularly undiagnosed and unre-
lated MFM patients was screened for newly identified and
previously reported HMERF-associated TTN mutations by
restriction analysis and additional verification by Sanger se-
quencing. We identified the p.Cys30071Arg mutation in
the index case of a Native American family (Family B). The
same p.Cys30071Arg mutation was also detected in the
index patient of a Spanish family (Family C) who was
suspected of having HMERF based on clinical and patho-
logical data.
Discussion
After Edström et al. [1] outlined a new disorder based
on analysis of patients with an adult-onset proximal
Figure 7 Schematic representation of super-repeats 10 and 11 (SR-10 and SR-11) of the A-band and the kinase domain of titin. Fn3
domains are shown in red, Ig-like domains in white and the kinase domain in black. Super-repeat boundaries are indicated by dividing lines. TTN
mutation p.Gly30150Asp identified in Family A and the p.Cys30071Arg identified in North European families [7,8] have occurred in an FN3
domain of the 10th large super-repeat numbering A150 (according to [33]). The previously reported p.Arg32450Trp mutation [5] is located at the
N-terminal helix (alphaR1) of the kinase domain. Bottom: Amino acid conservation (source: http://genome.ucsc.edu) from Zebrafish to Human in
the titin domain A150 containing Cys30071 and Gly30150 mutated in HMERF (indicated by arrows).
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http://www.biomedcentral.com/1471-2377/13/29myopathy and early respiratory muscle weakness, a
number of similar cases were described. The clinical/
pathological definitions of this disease later named
HMERF were significantly refined and extended [2,3].
Two Swedish families originally reported by Edström
et al. were genotyped, the disease-associated locus
assigned to chromosome 2q31 in the vicinity of the TTN
gene [34], and eventually a p.Arg32450Trp mutation in
the kinase domain of titin was discovered [5]. Further
attempts at finding HMERF-causing TTN mutations
were hampered by the enormous size of this gene. Next
generation sequencing opened up opportunities for new
discoveries. Using this technology, the p.Cys30071Arg
TTN mutation was recently identified as the cause of
HMERF in North European families [7,8].
Whole exome sequencing performed on five affected
members of Family A showed two variants, c.175C>T:p.
Arg59Cys in CDC2 on chromosome 10q21.1 and
c.90674G>A:p.Gly30150Asp in TTN on chromosome
2q31 as having the highest deleteriousness scores. Both
are segregating with the disease. CDC2 variant was
excluded on the basis that it was not evidently deficient in
western analysis and had been recorded in the general
population thus suggesting that this variant is rather a rare
benign polymorphism (rs8755). The TTN p.Gly30150Asp
change is located in the highly conserved titin A-band and
not present in any available SNP database. The final selec-
tion of the TTN mutation was helped by reports of findingthe HMERF-associated p.Cys30071Arg mutation in North
European families [7,8]. Screening of 45 additional familial
and sporadic patients in which the role of MFM-
associated genes have been excluded led to the identifica-
tion of the TTN p.Cys30071Arg mutation in the index pa-
tient of family B originating from Native American
population; this same mutation was found in a HMERF
patient from Spain, indicating that missense mutations in
TTN are the cause of HMERF in diverse populations.
We compared the disease phenotypes in groups of
HMERF patients originating from different populations
and carrying various TTN mutations (Table 4). Although
the number of patients in each column is small for a
comprehensive comparison, there is enough data to
summarise the basic features of this disease. The pattern
of inheritance is autosomal dominant. The age of disease
onset is in the teens or the 20-s in most patients; it was
at somewhat older age in the U.K. family [2,7]. Pelvic
and shoulder girdle weakness was the earliest and pre-
dominant sign in every patient, with several exceptions
in the family from the U.K. which showed weakness
in distal muscles at presentation. In the U.S. family,
we observed characteristic sternocleidomastoid/trapezius
muscle weakness and atrophy without scapular win-
ging, and calf hypertrophy that was evident before mus-
cle wasting has developed with disease progression. Re-
spiratory function was affected early in the disease:
about a third of patients presented with respiratory
Table 4 Comparative clinical characteristics of reported patients with confirmed titin mutations













Inheritance pattern AD AD AD AD AD
Country Sweden Sweden Britain U.S. Spain/Canada
No. of studied patients 7 8 22 5 2
Onset age, mean (range), yrs 24.8 28.8 44.6 19 29
(14–40) (18–40) (22–71) (13–29) (22–36)
Gender (woman/man) 5/2 5/3 12/10 (0/5) 2/0
Distribution of muscle
weakness
Pelvic girdle 7/7 8/8 15/21 5/5 2/2
Shoulder girdle 7/7 4/7 10/22 3/5 1/2
Neck flexors 7/7 8/8 7/22 5/5 2/2
Trunk muscles Nr 8/8 Nr 3/5 1/2
Knee flexors Nr 7/8 7/22 3/5 1/2
Knee extensors Nr 2/8 6/22 3/5 2/2
Ankle dorsiflexors 2/7 7/8 17/22 5/5 2/2
Plantar flexors Nr 1/8 5/22 3/5 0/2
Finger extensors 4/7 1/8 4/22 3/5 2/2
Finger flexors Nr 1/8 3/22 2/5 0/2
Respiratory failure 7/7 8/8 12/22 2/5 2/2
Mildly elevated CK 1/7 1/1 11/19 1/1 2/2
Myopathic EMG 7/7 1/1 11/18 1/1 2/2
Outcome
Wheelchair dependency Nr 1/8 2/22 2/5 1/2
Ventilation dependency 4/7 4/8 6/22 2/5 2/2
Death before age 65 Nr 1/1 Nr 2/2 1/1
AD – autosomal dominant; Nr – not reported.
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the first year of illness, and two thirds had moderate
respiratory failure requiring ventilation support before
the fifth year of illness while they were still ambulant.
With disease progression, most of the patients developed
weakness in the ankle dorsiflexors. None of the HMERF
patients had cardiac involvement, although mutations in
TTN are known to cause dilated and hypertrophic
cardiomyopathy [14]. This may depend on differential ex-
pression of tissue-specific titin isoforms. Creatine kinase
(CK) levels were normal or slightly elevated. Muscle im-
aging in our patient showed characteristic and diagnostic-
ally significant abnormality in iliopsoas, obturator
externus, semitendinosus, gracilis and sartorius muscles
on the thigh level and the peroneal group at the mid-
lower-leg level, which is in agreement with previous obser-
vations [3,8]. Disease outcome for patients with HMERF
is one of the worst known for an autosomal dominant
adult-onset myopathy because it leads to incapacity,wheelchair dependency, and the need for permanent ven-
tilatory support relatively early in life.
The most characteristic abnormalities on muscle biop-
sies of patients with HMERF are the small round well
defined eosinophilic cytoplasmic bodies. Patients with
advanced disease show in addition large diffuse poly-
morphic accumulations of material corresponding to
protein aggregates that contain F-actin, dystrophin,
myotilin, and filamin C as we determined by immuno-
histochemistry and as shown in other series of HMERF
patients. In agreement with previous observations [4],
desmin was focally increased under the sarcolemma and
at the periphery of cytoplasmic bodies but not within
them. Interestingly, we detected TDP-43 aggregates in
the sarcoplasm of several fibers. TDP-43 (TAR-DNA-
binding protein-43) is typically found in cytoplasmic
inclusions of patients with motor neuron disease and
frontotemporal lobar degeneration [35]. TDP-43-stained
aggregates were also found in affected muscle fibres in
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myositis, GNE myopathy, myofibrillar myopathies, and
oculopharyngeal muscular dystrophy [36-38].
Ultrastructural analysis in two of our patients revealed
early disintegration of the Z-disks followed by myofibril-
lar dissolution and aggregation of degraded filaments.
Taken together, the immunohistochemical and ultra-
structural features are closely reminiscent of those seen
in MFM and based on these morphological characteris-
tics HMERF can be considered a member of the same
large group of muscle diseases recently named protein
aggregate myopathies (PAMs) [39]. While differential
diagnosis of HMERF is solidly based on the presence of
cytoplasmic bodies, it needs to be indicated that cyto-
plasmic bodies observed in HMERF-affected muscles are
reminiscent of and should be distinguished from the
globular cytoplasmic inclusions seen in muscle biopsies
of a fraction of patients with Pompe disease [40]. This is
of major importance since early respiratory weakness is
also frequently observed in patients suffering from the
late-onset Pompe disease [41]. Strong acid phosphatase
activity and lack of filaments or any other Z-disc compo-
nents in Pompe disease structures [40] may help to
distinguish them from cytoplasmic bodies found in
HMERF. Accumulation of cytoplasmic and occasionally
intranuclear tubulofilaments have been noted in pa-
tients with MFM, particularly myotilinopathy [42-44]
and C-filaminopathy [45,46], demonstrating that the
boundaries between HMERF and MFM need to be de-
fined more clearly. Indeed, the combination of proximal
and distal weakness and respiratory failure, muscle imaging
results and myofibrillar inclusions on muscle histopath-
ology make HMERF similar to desminopathy or alphaB-
crystallinopathy. A major distinguishing feature is the lack
of cardiac involvement which is seen in the majority of pa-
tients with desminopathy or alphaB-crystallinopathy [47]
and, importantly, granulofilamentous material which con-
stitutes the ultrastructural hallmark of desminopathy and
alphaB-crystallinopathy [27,44,48] is not a feature of
HMERF.
There is very limited data on possible consequences of
disruptions in FN3 elements within the conserved titin
A-band region, although there has been a report of a
mutation occurring within FN3 domains in patients with
arrhythmogenic right ventricular cardiomyopathy [49]. A
three-dimensional structure of an FN3 domain revealed
that many of its conserved residues are exposed on the
surface of the domain; most likely, they serve as binding
sites specifically binding sub-fragment 1 of myosin [20].
Residues replaced by HMERF mutations are known to be
highly conserved, specifically the cysteine residues that are
the most conserved throughout the entire A-band struc-
ture [20]. If the previously proposed structural model of
A77 [33] reflects the structure of other A-band FN3domains, the mutated residues Cys30071 and Gly30150 are
located in the side chain that most likely serve as a binding
site. Some indications regarding the pathomechanisms in
HMERF come from the results of experimental manipula-
tions with FN3 domains that led to an increased rate of
molecular aggregation [50].
The p.Arg32450Trp mutation in the kinase domain
identified in Swedish families may affect its ability to
send signals regarding overextention and other abnormal
physiological events in the contracting muscle [51].
Specifically, the mutation disrupts the interaction of titin
with NBR1 protein, a ubiquitin-binding scaffold protein,
and in turn with p62/SQSTM1 and MURF2. The NRB1/
P62 complex plays an important role in autophagic and
proteasome degradation of ubiquitinated proteins [5].
The affected muscle shows disrupted myofibrils, NBR1
localization in cytoplasmic bodies, and aggregation of the
p62/SQSTM1 complex with myofibrillar proteins. This
suggests that the p.Arg32450Trp mutation affects the abil-
ity of titin to control muscle protein turnover and through
this action disrupts muscle sarcomere maintenance.
Conclusions
Molecular analysis of patients initially diagnosed as myo-
fibrillar myopathy led to the identification of a novel
TTN p.Gly30150Asp that is now added to two other
known TTN mutations causing HMERF. Although there
is strong phenotypic similarity between MFM and
HMERF, we emphasize distinct clinical/pathological fea-
tures that can serve as a basis for HMERF diagnosis in
patients carrying any of the 3 known TTN mutations
and originating from diverse world populations. The
newly identified p.Gly30150Asp and the other recently
discovered p.Cys30071Arg mutation are localized to a
side chain of fibronectin type III element A150 of the
10th C-zone super-repeat of titin.
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